Halle (Saale) / Munich, Germany, May 11, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon; or the Company), a clinical stage company focused on discovery and development of […]
Substantial progress in clinical development of QPCT/L inhibitor varoglutamstat, EU and U.S. clinical studies in AD on track FDA Fast Track designation for lead product candidate […]
Halle (Saale) / Munich, Germany, April 21, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
HALLE (SAALE) / MUNICH, GERMANY, April 20, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Halle (Saale) / Munich, Germany, April […]
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Halle (Saale) / Munich, Germany, March […]
HALLE (SAALE) / MUNICH, GERMANY, March 7, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Halle (Saale) / Munich, Germany and Nanjing, China, February 28, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and […]
HALLE (SAALE) / MUNICH, GERMANY, January 4, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]